Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$38.96 USD

38.96
4,990,122

-0.25 (-0.64%)

Updated Oct 17, 2024 04:00 PM ET

After-Market: $38.98 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sheraz Mian headshot

Q1 Earnings Scorecard and Analyst Reports for Netflix, Costco & Others

by Sheraz Mian

In addition to new research reports on 16 major stocks, including Netflix (NFLX), Costco (COST) and others, we also have real-time Q1 earnings scorecard today.

Sanofi and Glaxo Collaborate to Develop Coronavirus Vaccine

by Zacks Equity Research

Sanofi (SNY) and Glaxo are contributing their proven technologies to develop a coronavirus vaccine, which may be manufactured at large scale.

Kinjel Shah headshot

Pharma Q1 Earnings Begin With J&J's Report: 3 Stocks to Buy

by Kinjel Shah

Investors typically look at J&J's (JNJ) results for signals about how the rest of the big drugmakers will fare.

Ritujay Ghosh headshot

Pharma Stocks Rally on Sanofi, GSK Coronavirus Vaccine Tie-Up

by Ritujay Ghosh

If successful, the Sanofi (SNY) and GlaxoSmithKline plc (GSK) vaccine would be available in the second half of 2021. Shares of drugmakers jumped on the news.

GlaxoSmithKline (GSK) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, GlaxoSmithKline (GSK) closed at $38.08, marking a +1.47% move from the previous day.

Merck's Keytruda Gets FDA's Priority Review for Solid Tumors

by Zacks Equity Research

Merck's (MRK) sBLA seeking approval of Keytruda for advanced solid tumors, based on biomarker, regardless of tumor type, gets FDA's priority review.

Sweta Jaiswal, FRM headshot

Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress

by Sweta Jaiswal, FRM

The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.

Glaxo to Buy Stake in Vir Biotech, Signs Coronavirus Deal

by Zacks Equity Research

Glaxo (GSK) set to invest $250 million in Vir Biotechnology. Vir's stock soars.

Myriad Genetics' (MYGN) BRACAnalysis Gets Japan Reimbursement

by Zacks Equity Research

Myriad Genetics (MYGN) launches BRACAnalysis Diagnostic System in Japan, after receiving reimbursement for the system, which will enable easier identification of HBOC patients.

Glaxo's Nasal Polyps Study on Nucala Meets Primary Endpoints

by Zacks Equity Research

Glaxo's (GSK) phase III study on Nucala in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) meets co-primary endpoints.

Sweta Jaiswal, FRM headshot

Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development

by Sweta Jaiswal, FRM

The rampant race to introduce a vaccine for the COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.

Kinjel Shah headshot

Lilly Halts Enrollment, Biotechs Focus to Find Coronavirus Cure

by Kinjel Shah

Supply-chain disruptions due to coronavirus outbreak may hurt biotech companies' first-quarter earnings. However, those making treatments/vaccines may make huge profits if their products get approval.

Kinjel Shah headshot

Glaxo's Long-Acting HIV Regimen Cabenuva Gets Canada's Nod

by Kinjel Shah

Glaxo's (GSK) long-acting injectable regimen of cabotegravir and rilpivirine gets its first approval for the treatment of HIV-1 infection in virologically-suppressed adults

The Zacks Analyst Blog Highlights: ORCL, CSCO, NFLX, GSK and CCI

by Zacks Equity Research

The Zacks Analyst Blog Highlights: ORCL, CSCO, NFLX, GSK and CCI

Madeleine Johnson headshot

These 10 Drug Companies are Testing a Coronavirus Vaccine

by Madeleine Johnson

As the coronavirus pandemic continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.

Mark Vickery headshot

Top Research Reports for Oracle, Cisco & Netflix

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Cisco Systems (CSCO) and Netflix (NFLX).

Kaibalya Pravo Dey headshot

Coronavirus Vaccine Trial Begins, Biotech Competition Heats Up

by Kaibalya Pravo Dey

While the overall vaccine development process has been impressively fast so far, it might take 12-18 months to fully validate a potential vaccine.

Kinjel Shah headshot

AstraZeneca/Merck's Lynparza Combo Ovarian Cancer Study Fails

by Kinjel Shah

AstraZeneca (AZN)/Merck's (MRK) study evaluating cediranib added to Lynparza fails to meet the primary endpoint of PFS in patients with platinum-sensitive relapsed ovarian cancer

Agenus (AGEN) Q4 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Agenus (AGEN) betters loss estimates and also beats on sales in the fourth quarter. The company gets a Fast Track tag for balstilimab & zalifrelimab combo to address the second-line cervical cancer.

Roche's (RHHBY) Coronavirus Test Achieves EUA From the FDA

by Zacks Equity Research

Roche's (RHHBY) cobas SARS-CoV-2 Test for the qualitative detection of SARS-CoV-2, the virus that causes the COVID-19 disease, gets EUA from the FDA.

Gilead (GILD) Announces Positive Long-Term Results on Descovy

by Zacks Equity Research

Gilead (GILD) announces long-term results from the DISCOVER study, which showed that Descovy is effective for HIV prevention with non-inferior efficacy to Truvada.

AbbVie Backs Studies on HIV Drug Kaletra for Coronavirus Cure

by Zacks Equity Research

AbbVie (ABBV) donates Kaletra/Aluvia to the government of China for experimental use in coronavirus treatment

Mylan-Upjohn Merger in Focus, Coronavirus Might Hit Supply

by Zacks Equity Research

Mylan's (MYL) merger with Upjohn is in focus as the former looks to revive its business. However, the coronavirus epidemic can hit the company's supply-chain operations.

Regeneron (REGN) Gains from Focus on Coronavirus Treatments

by Zacks Equity Research

Regeneron's (REGN) shares grow year to date owing to focus on developing a treatment for combating the novel coronavirus.

Gilead to Buy Immuno-Oncology Company Forty Seven for $4.9B

by Zacks Equity Research

Gilead (GILD) looks to strengthen its immuno-oncology research and development portfolio with the acquisition of Forty Seven.